<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461967</url>
  </required_header>
  <id_info>
    <org_study_id>WP25752</org_study_id>
    <secondary_id>2011-002053-54</secondary_id>
    <nct_id>NCT01461967</nct_id>
  </id_info>
  <brief_title>A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Single and Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food) and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, cross-over study will assess the safety,
      pharmacokinetics and pharmacodynamics of RO5508887 in healthy volunteers. In Part 1, subjects
      will be randomized to receive single ascending doses of either RO5508887 or placebo. In Part
      2, subjects will receive a single dose of RO5508887 on two occasions, with or without food.
      Anticipated time on study is up to 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability: Incidence of adverse events</measure>
    <time_frame>up to approximately 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma concentrations of RO5508887</measure>
    <time_frame>predose, 1.5, 3, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Urine levels of RO5508887</measure>
    <time_frame>predose to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Plasma levels of markers of amyloid deposition (Abeta1-40/Abeta1-42)</measure>
    <time_frame>predose, 1.5, 3, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 24, 48, 72, 96, 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on pharmacokinetics (plasma concentrations) of a single dose of RO5508887</measure>
    <time_frame>predose, 1.5, 3, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 24, 36, 48, 60, 72 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single ascending doses</description>
    <arm_group_label>Part 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5508887</intervention_name>
    <description>Single ascending doses</description>
    <arm_group_label>Part 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5508887</intervention_name>
    <description>Single doses</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers, 18-45 (Part 1) or 18-65 (Part 2) years of age inclusive;
             healthy status is defined by absence of evidence of any active or chronic disease

          -  Body Mass Index (BMI) 18 to 30 kg/m2 inclusive

          -  Male subjects must use a barrier method of contraception for the duration of the study
             and for 30 days after the last dose

        Exclusion Criteria:

          -  Suspicion of regular consumption of drugs of abuse

          -  Regular smoker (&gt;5 cigarettes, &gt;1 pipeful or &gt;1 cigar per day)

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  History of hypersensitivity or severe drug reaction

          -  Participation in an investigational drug or device study within three months before
             the first drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

